Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Multiple Myeloma 181Recurrence 32Neoplasms, Plasma Cell 16Lymphoma 11Waldenstrom Macroglobulinemia 6Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Smoldering Multiple Myeloma 4Leukemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Plasma Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Disease 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1

Interventions

Cisplatin 12Everolimus 10Nivolumab 8Etoposide 8Temozolomide 6Carboplatin 6atezolizumab 5Irinotecan 5Ipilimumab 5Fluorouracil 5Bevacizumab 5pembrolizumab 4lutetium Lu 177 dotatate 4Capecitabine 4avelumab 3Paclitaxel 3IFL protocol 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2cabozantinib 2belinostat 2azaspirane 2Topotecan 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × carfilzomib × Clear all
NCT02318784 2023-12-05

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
62 enrolled 10 charts
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡